Abstract
Organic cation transporters (OCTs) of the solute carrier family (SLC) 22 are the subject of intensive research because they mediate the transport of many clinically-relevant drugs such as the antidiabetic agent metformin, the opioid tramadol, and the antimigraine agent sumatriptan. OCT1 (SLC22A1) and OCT2 (SLC22A2) are highly expressed in human liver and kidney, respectively, while OCT3 (SLC22A3) shows a broader tissue distribution. As suggested from studies using knockout mice, particularly OCT2 and OCT3 appear to be of relevance for brain physiological function and drug response. The knowledge of genetic factors and epigenetic modifications affecting function and expression of OCTs is important for a better understanding of disease mechanisms and for personalized treatment of patients. This review briefly summarizes the impact of genetic variants and epigenetic regulation of OCTs in general. A comprehensive overview is given on the consequences of OCT2 and OCT3 knockout in mice and the implications of genetic OCT2 and OCT3 variants on central nervous system function in humans.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Aoki M, Terada T, Kajiwara M, Ogasawara K, Ikai I, Ogawa O, Katsura T, Inui K-I (2008) Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation. Am J Physiol Ren Physiol 295:F165–F170. https://doi.org/10.1152/ajprenal.90257.2008
Aoyama N, Takahashi N, Kitaichi K, Ishihara R, Saito S, Maeno N, Ji X, Takagi K, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iwata N, Inada T, Ozaki N (2006) Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. Alcohol Clin Exp Res 30:1644–1649. https://doi.org/10.1111/j.1530-0277.2006.00215.x
Bacq A, Balasse L, Biala G, Guiard B, Gardier AM, Schinkel A, Louis F, Vialou V, Martres M-P, Chevarin C, Hamon M, Giros B, Gautron S (2012) Organic cation transporter 2 controls brain norepinephrine and serotonin clearance and antidepressant response. Mol Psychiatry 17:926–939. https://doi.org/10.1038/mp.2011.87
Baganz NL, Horton RE, Calderon AS, Owens WA, Munn JL, Watts LT, Koldzic-Zivanovic N, Jeske NA, Koek W, Toney GM, Daws LC (2008) Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc Natl Acad Sci U S A 105:18976–18981. https://doi.org/10.1073/pnas.0800466105
Baganz N, Horton R, Martin K, Holmes A, Daws LC (2010) Repeated swim impairs serotonin clearance via a corticosterone-sensitive mechanism: organic cation transporter 3, the smoking gun. J Neurosci 30:15185–15195. https://doi.org/10.1523/JNEUROSCI.2740-10.2010
Bergen AW, Javitz HS, Krasnow R, Michel M, Nishita D, Conti DV, Edlund CK, Kwok P-Y, McClure JB, Kim RB, Hall SM, Tyndale RF, Baker TB, Benowitz NL, Swan GE (2014) Organic cation transporter variation and response to smoking cessation therapies. Nicotine Tob Res 16:1638–1646. https://doi.org/10.1093/ntr/ntu161
Brouwer KLR, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, Meibohm B, Nigam SK, Rieder M, de Wildt SN (2015) Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group. Clin Pharmacol Ther 98:266–287. https://doi.org/10.1002/cpt.176
Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, Volk C, Arndt P, Ulzheimer JC, Sonders MS, Baumann C, Waldegger S, Lang F, Koepsell H (1998) Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol 54:342–352. https://doi.org/10.1124/mol.54.2.342
César-Razquin A, Snijder B, Frappier-Brinton T, Isserlin R, Gyimesi G, Bai X, Reithmeier RA, Hepworth D, Hediger MA, Edwards AM, Superti-Furga G (2015) A call for systematic research on solute carriers. Cell 162:478–487. https://doi.org/10.1016/j.cell.2015.07.022
Chaves C, Campanelli F, Chapy H, Gomez-Zepeda D, Glacial F, Smirnova M, Taghi M, Pallud J, Perrière N, Declèves X, Menet M-C, Cisternino S (2020) An interspecies molecular and functional study of organic cation transporters at the blood-brain barrier: from rodents to humans. Pharmaceutics 12. https://doi.org/10.3390/pharmaceutics12040308
Chen L, Hong C, Chen EC, Yee SW, Xu L, Almof EU, Wen C, Fujii K, Johns SJ, Stryke D, Ferrin TE, Simko J, Chen X, Costello JF, Giacomini KM (2013) Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharm J 13:110–120. https://doi.org/10.1038/tpj.2011.60
Cheung KWK, van Groen BD, Spaans E, van Borselen MD, de Bruijn ACJM, Simons-Oosterhuis Y, Tibboel D, Samsom JN, Verdijk RM, Smeets B, Zhang L, Huang S-M, Giacomini KM, de Wildt SN (2019) A comprehensive analysis of ontogeny of renal drug transporters: mRNA analyses, quantitative proteomics, and localization. Clin Pharmacol Ther 106:1083–1092. https://doi.org/10.1002/cpt.1516
Couroussé T, Bacq A, Belzung C, Guiard B, Balasse L, Louis F, Le Guisquet A-M, Gardier AM, Schinkel AH, Giros B, Gautron S (2015) Brain organic cation transporter 2 controls response and vulnerability to stress and GSK3β signaling. Mol Psychiatry 20:889–900. https://doi.org/10.1038/mp.2014.86
Daws LC (2009) Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy. Pharmacol Ther 121:89–99. https://doi.org/10.1016/j.pharmthera.2008.10.004
Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O’Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40:316–321. https://doi.org/10.1038/ng.90
Farthing CA, Sweet DH (2014) Expression and function of organic cation and anion transporters (SLC22 family) in the CNS. Curr Pharm Des 20:1472–1486. https://doi.org/10.2174/13816128113199990456
Feng N, Lowry CA, Lukkes JL, Orchinik M, Forster GL, Renner KJ (2010) Organic cation transporter inhibition increases medial hypothalamic serotonin under basal conditions and during mild restraint. Brain Res 1326:105–113. https://doi.org/10.1016/j.brainres.2010.02.044
Fisel P, Schaeffeler E, Schwab M (2016) DNA methylation of ADME genes. Clin Pharmacol Ther 99:512–527. https://doi.org/10.1002/cpt.343
Fisel P, Nies AT, Schaeffeler E, Schwab M (2017) The importance of drug transporter characterization to precision medicine. Expert Opin Drug Metab Toxicol 13:361–365. https://doi.org/10.1080/17425255.2017.1290083
Frick A, Suzuki O, Butz N, Chan E, Wiltshire T (2013) In vitro and in vivo mouse models for pharmacogenetic studies. Methods Mol Biol 1015:263–278. https://doi.org/10.1007/978-1-62703-435-7_17
Garbarino VR, Santos TA, Nelson AR, Zhang WQ, Smolik CM, Javors MA, Daws LC, Gould GG (2019) Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice. Pharmacol Res 140:21–32. https://doi.org/10.1016/j.phrs.2018.11.013
Gasser PJ, Lowry CA, Orchinik M (2006) Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: potential role for organic cation transporter 3 in stress-induced modulation of monoaminergic neurotransmission. J Neurosci 26:8758–8766. https://doi.org/10.1523/JNEUROSCI.0570-06.2006
Gasser PJ, Orchinik M, Raju I, Lowry CA (2009) Distribution of organic cation transporter 3, a corticosterone-sensitive monoamine transporter, in the rat brain. J Comp Neurol 512:529–555. https://doi.org/10.1002/cne.21921
Gasser PJ, Hurley MM, Chan J, Pickel VM (2017) Organic cation transporter 3 (OCT3) is localized to intracellular and surface membranes in select glial and neuronal cells within the basolateral amygdaloid complex of both rats and mice. Brain Struct Funct 222:1913–1928. https://doi.org/10.1007/s00429-016-1315-9
Gaudelot K, Gibier J-B, Pottier N, Hémon B, van Seuningen I, Glowacki F, Leroy X, Cauffiez C, Gnemmi V, Aubert S, Perrais M (2017) Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. Tumour Biol 39:1010428317707372. https://doi.org/10.1177/1010428317707372
Geier EG, Chen EC, Webb A, Papp AC, Yee SW, Sadee W, Giacomini KM (2013) Profiling solute carrier transporters in the human blood-brain barrier. Clin Pharmacol Ther 94:636–639. https://doi.org/10.1038/clpt.2013.175
Giacomini KM, Huang S-M, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236. https://doi.org/10.1038/nrd3028
Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H (1997) Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16:871–881. https://doi.org/10.1089/dna.1997.16.871
Goswami S, Gong L, Giacomini K, Altman RB, Klein TE (2014) PharmGKB summary: very important pharmacogene information for SLC22A1. Pharmacogenet Genomics 24:324–328. https://doi.org/10.1097/FPC.0000000000000048
Grottelli S, Ferrari I, Pietrini G, Peirce MJ, Minelli A, Bellezza I (2016) The role of cyclo(his-pro) in neurodegeneration. Int J Mol Sci 17. https://doi.org/10.3390/ijms17081332
Gründemann D, Schechinger B, Rappold GA, Schömig E (1998) Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci 1:349–351. https://doi.org/10.1038/1557
Haag C, Berkels R, Gründemann D, Lazar A, Taubert D, Schömig E (2004) The localisation of the extraneuronal monoamine transporter (EMT) in rat brain. J Neurochem 88:291–297. https://doi.org/10.1111/j.1471-4159.2004.02180.x
Hahn D, Emoto C, Vinks AA, Fukuda T (2017) Developmental changes in hepatic organic cation transporter OCT1 protein expression from neonates to children. Drug Metab Dispos 45:23–26. https://doi.org/10.1124/dmd.116.072256
Hengen N, Lizer MH, Kidd RS (2011) Evaluation of genetic variations in organic cationic transporter 3 in depressed and nondepressed subjects. ISRN Pharmacol 2011:161740. https://doi.org/10.5402/2011/161740
Hill JE, Gasser PJ (2013) Organic cation transporter 3 is densely expressed in the intercalated cell groups of the amygdala: anatomical evidence for a stress hormone-sensitive dopamine clearance system. J Chem Neuroanat 52:36–43. https://doi.org/10.1016/j.jchemneu.2013.04.007
Holliday R (2006) Epigenetics: a historical overview. Epigenetics 1:76–80. https://doi.org/10.4161/epi.1.2.2762
Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson AA, Li Y, Hong KW, DiGiacomo D, Xia SH, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg MB, Cavaletti G, Pabla N, Hu S, Sparreboom A (2020) Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. J Clin Invest 130:4601–4606. https://doi.org/10.1172/JCI136796
Inazu M, Takeda H, Matsumiya T (2003) Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes. J Neurochem 84:43–52. https://doi.org/10.1046/j.1471-4159.2003.01566.x
Iwata K, Aizawa K, Kamitsu S, Jingami S, Fukunaga E, Yoshida M, Yoshimura M, Hamada A, Saito H (2012) Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol 16:843–851. https://doi.org/10.1007/s10157-012-0638-y
Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O'Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, Neale BM, Daly MJ, MacArthur DG (2020) The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581:434–443. https://doi.org/10.1038/s41586-020-2308-7
Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E, Keil A, Eichelbaum M, Koepsell H (2002) Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12:591–595. https://doi.org/10.1097/00008571-200211000-00002
Kitaichi K, Fukuda M, Nakayama H, Aoyama N, Ito Y, Fujimoto Y, Takagi K, Takagi K, Hasegawa T (2005) Behavioral changes following antisense oligonucleotide-induced reduction of organic cation transporter-3 in mice. Neurosci Lett 382:195–200. https://doi.org/10.1016/j.neulet.2005.03.014
Koepsell H (2020) Organic cation transporters in health and disease. Pharmacol Rev 72:253–319. https://doi.org/10.1124/pr.118.015578
Kozyra M, Ingelman-Sundberg M, Lauschke VM (2017) Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med 19:20–29. https://doi.org/10.1038/gim.2016.33
Lazar A, Walitza S, Jetter A, Gerlach M, Warnke A, Herpertz-Dahlmann B, Gründemann D, Grimberg G, Schulz E, Remschmidt H, Wewetzer C, Schömig E (2008) Novel mutations of the extraneuronal monoamine transporter gene in children and adolescents with obsessive-compulsive disorder. Int J Neuropsychopharmacol 11:35–48. https://doi.org/10.1017/S1461145707007742
Li L, He M, Zhou L, Miao X, Wu F, Huang S, Dai X, Wang T, Wu T (2015) A solute carrier family 22 member 3 variant rs3088442 G-->A associated with coronary heart disease inhibits lipopolysaccharide-induced inflammatory response. J Biol Chem 290:5328–5340. https://doi.org/10.1074/jbc.M114.584953
Lin C-J, Tai Y, Huang M-T, Tsai Y-F, Hsu H-J, Tzen K-Y, Liou H-H (2010) Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. J Neurochem 114:717–727. https://doi.org/10.1111/j.1471-4159.2010.06801.x
Long G, Zhang G, Zhang F, Ye D, Yang D, Yang Y (2018) Relationship between SLC22A1 and SLC22A4 gene polymorphisms and risk of type 2 diabetes in Chinese Han population. Clin Lab 64:1357–1361. https://doi.org/10.7754/Clin.Lab.2018.180129
Matic M, de Wildt SN, Tibboel D, van Schaik RHN (2017) Analgesia and opioids: a pharmacogenetics shortlist for implementation in clinical practice. Clin Chem 63:1204–1213. https://doi.org/10.1373/clinchem.2016.264986
Matsui T, Nakata T, Kobayashi Y (2016) Localization of organic cation transporter 2 (OCT2) in monoaminergic and cholinergic axon terminals of the mouse brain. Neurosci Lett 633:118–124. https://doi.org/10.1016/j.neulet.2016.09.025
Matthaei J, Kuron D, Faltraco F, Knoch T, dos Santos Pereira JN, Abu AM, Prukop T, Brockmoller J, Tzvetkov MV (2016) OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther 99:633–641. https://doi.org/10.1002/cpt.317
Mayer FP, Schmid D, Owens WA, Gould GG, Apuschkin M, Kudlacek O, Salzer I, Boehm S, Chiba P, Williams PH, Wu H-H, Gether U, Koek W, Daws LC, Sitte HH (2018) An unsuspected role for organic cation transporter 3 in the actions of amphetamine. Neuropsychopharmacology 43:2408–2417. https://doi.org/10.1038/s41386-018-0053-5
Meyer UA, Zanger UM, Schwab M (2013) Omics and drug response. Annu Rev Pharmacol Toxicol 53:475–502. https://doi.org/10.1146/annurev-pharmtox-010510-100502
Meyer MJ, Neumann VE, Friesacher HR, Zdrazil B, Brockmöller J, Tzvetkov MV (2019) Opioids as substrates and inhibitors of the genetically highly variable organic cation transporter OCT1. J Med Chem 62:9890–9905. https://doi.org/10.1021/acs.jmedchem.9b01301
Mooij MG, Nies AT, Knibbe CAJ, Schaeffeler E, Tibboel D, Schwab M, de Wildt SN (2016) Development of human membrane transporters: drug disposition and pharmacogenetics. Clin Pharmacokinet 55:507–524. https://doi.org/10.1007/s40262-015-0328-5
Nies AT, Koepsell H, Damme K, Schwab M (2011) Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol:105–167. https://doi.org/10.1007/978-3-642-14541-4_3
Ohishi Y, Nakamuta M, Ishikawa N, Saitoh O, Nakamura H, Aiba Y, Komori A, Migita K, Yatsuhashi H, Fukushima N, Kohjima M, Yoshimoto T, Fukuizumi K, Ishibashi M, Nishino T, Shirabe K, Taketomi A, Maehara Y, Ishibashi H, Nakamura M (2014) Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol 49:332–342. https://doi.org/10.1007/s00535-013-0795-0
Park T-J, Kim J-H, Bae J-S, Park B-L, Cheong HS, Chun J-Y, Lee J-S, Kim JY, Pasaje CF, Cho SH, Uh S-T, Kim M-K, Choi IS, Koh IS, Park C-S, Shin HD (2011) Possible association of SLC22A2 polymorphisms with aspirin-intolerant asthma. Int Arch Allergy Immunol 155:395–402. https://doi.org/10.1159/000321267
Peter B, Lancaster H, Vose C, Fares A, Schrauwen I, Huentelman M (2017) Two unrelated children with overlapping 6q25.3 deletions, motor speech disorders, and language delays. Am J Med Genet A 173:2659–2669. https://doi.org/10.1002/ajmg.a.38385
Prasad B, Gaedigk A, Vrana M, Gaedigk R, Leeder JS, Salphati L, Chu X, Xiao G, Hop C, Evers R, Gan L, Unadkat JD (2016) Ontogeny of hepatic drug transporters as quantified by LC-MS/MS proteomics. Clin Pharmacol Ther 100:362–370. https://doi.org/10.1002/cpt.409
Rappold PM, Cui M, Chesser AS, Tibbett J, Grima JC, Duan L, Sen N, Javitch JA, Tieu K (2011) Paraquat neurotoxicity is mediated by the dopamine transporter and organic cation transporter-3. Proc Natl Acad Sci U S A 108:20766–20771. https://doi.org/10.1073/pnas.1115141108
Ren A, Sun S, Li S, Chen T, Shu Y, Du M, Zhu L (2019) Genetic variants in SLC22A3 contribute to the susceptibility to colorectal cancer. Int J Cancer 145:154–163. https://doi.org/10.1002/ijc.32079
Rieger JK, Klein K, Winter S, Zanger UM (2013) Expression variability of absorption, distribution, metabolism, excretion-related microRNAs in human liver: influence of nongenetic factors and association with gene expression. Drug Metab Dispos 41:1752–1762. https://doi.org/10.1124/dmd.113.052126
Schaeffeler E, Hellerbrand C, Nies AT, Winter S, Kruck S, Hofmann U, van der Kuip H, Zanger UM, Koepsell H, Schwab M (2011) DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med 3:82. https://doi.org/10.1186/gm298
Schärfe CPI, Tremmel R, Schwab M, Kohlbacher O, Marks DS (2017) Genetic variation in human drug-related genes. Genome Med 9:117. https://doi.org/10.1186/s13073-017-0502-5
Seitz T, Stalmann R, Dalila N, Chen J, Pojar S, Dos Santos Pereira JN, Krätzner R, Brockmöller J, Tzvetkov MV (2015) Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. Genome Med 7:56. https://doi.org/10.1186/s13073-015-0172-0
Shu Y, Leabman MK, Feng B, Mangravite LM, Huang CC, Stryke D, Kawamoto M, Johns SJ, DeYoung J, Carlson E, Ferrin TE, Herskowitz I, Giacomini KM (2003) Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A 100:5902–5907. https://doi.org/10.1073/pnas.0730858100
Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, Brett CM, Giacomini KM (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422–1431. https://doi.org/10.1172/JCI30558
Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF, Sparreboom A (2013) Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A 110:11199–11204. https://doi.org/10.1073/pnas.1305321110
Stamer UM, Musshoff F, Stüber F, Brockmöller J, Steffens M, Tzvetkov MV (2016) Loss-of-function polymorphisms in the organic cation transporter OCT1 are associated with reduced postoperative tramadol consumption. Pain 157:2467–2475. https://doi.org/10.1097/j.pain.0000000000000662
Stieger B, Gao B (2015) Drug transporters in the central nervous system. Clin Pharmacokinet 54:225–242. https://doi.org/10.1007/s40262-015-0241-y
Sweet DH, Miller DS, Pritchard JB (2001) Ventricular choline transport: a role for organic cation transporter 2 expressed in choroid plexus. J Biol Chem 276:41611–41619. https://doi.org/10.1074/jbc.M108472200
Taubert D, Grimberg G, Stenzel W, Schömig E (2007) Identification of the endogenous key substrates of the human organic cation transporter OCT2 and their implication in function of dopaminergic neurons. PLoS One 2:e385. https://doi.org/10.1371/journal.pone.0000385
Trégouët D-A, König IR, Erdmann J, Munteanu A, Braund PS, Hall AS, Grosshennig A, Linsel-Nitschke P, Perret C, DeSuremain M, Meitinger T, Wright BJ, Preuss M, Balmforth AJ, Ball SG, Meisinger C, Germain C, Evans A, Arveiler D, Luc G, Ruidavets J-B, Morrison C, van der Harst P, Schreiber S, Neureuther K, Schäfer A, Bugert P, El Mokhtari NE, Schrezenmeir J, Stark K, Rubin D, Wichmann H-E, Hengstenberg C, Ouwehand W, Ziegler A, Tiret L, Thompson JR, Cambien F, Schunkert H, Samani NJ (2009) Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease. Nat Genet 41:283–285. https://doi.org/10.1038/ng.314
Tzvetkov MV (2017) OCT1 pharmacogenetics in pain management: is a clinical application within reach? Pharmacogenomics 18:1515–1523. https://doi.org/10.2217/pgs-2017-0095
Tzvetkov MV, Dalila N, Faltraco F (2016) Genetic variability in organic cation transporters: pathophysiological manifestations and consequences for drug pharmacokinetics and efficacy. In: Ciarimboli G, Gautron S, Schlatter E (eds) Organic cation transporters. Springer, Cham, pp 93–137. https://doi.org/10.1007/978-3-319-23793-0_4
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, Navani S, Szigyarto CA-K, Odeberg J, Djureinovic D, Takanen JO, Hober S, Alm T, Edqvist P-H, Berling H, Tegel H, Mulder J, Rockberg J, Nilsson P, Schwenk JM, Hamsten M, von Feilitzen K, Forsberg M, Persson L, Johansson F, Zwahlen M, von Heijne G, Nielsen J, Pontén F (2015) Proteomics. Tissue-based map of the human proteome. Science 347:1260419. https://doi.org/10.1126/science.1260419
van der Wouden CH, van Rhenen MH, Jama WOM, Ingelman-Sundberg M, Lauschke VM, Konta L, Schwab M, Swen JJ, Guchelaar H-J (2019) Development of the PGx-passport: a panel of actionable germline genetic variants for pre-emptive pharmacogenetic testing. Clin Pharmacol Ther 106:866–873. https://doi.org/10.1002/cpt.1489
Vialou V, Amphoux A, Zwart R, Giros B, Gautron S (2004) Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci 24:2846–2851. https://doi.org/10.1523/JNEUROSCI.5147-03.2004
Vialou V, Balasse L, Callebert J, Launay J-M, Giros B, Gautron S (2008) Altered aminergic neurotransmission in the brain of organic cation transporter 3-deficient mice. J Neurochem 106:1471–1482. https://doi.org/10.1111/j.1471-4159.2008.05506.x
Winter S, Fisel P, Büttner F, Rausch S, D'Amico D, Hennenlotter J, Kruck S, Nies AT, Stenzl A, Junker K, Scharpf M, Hofmann U, van der Kuip H, Fend F, Ott G, Agaimy A, Hartmann A, Bedke J, Schwab M, Schaeffeler E (2016) Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenes. Sci Rep 6:29930. https://doi.org/10.1038/srep29930
Winter S, Fisel P, Büttner F, Nies AT, Stenzl A, Bedke J, Schwab M, Schaeffeler E (2017) Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin”. Sci Transl Med 9. https://doi.org/10.1126/scitranslmed.aal2439
Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V (2000) Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Ren Physiol 279:F449–F458. https://doi.org/10.1152/ajprenal.2000.279.3.F449
Wu K-C, Lu Y-H, Peng Y-H, Tsai T-F, Kao Y-H, Yang H-T, Lin C-J (2015) Decreased expression of organic cation transporters, Oct1 and Oct2, in brain microvessels and its implication to MPTP-induced dopaminergic toxicity in aged mice. J Cereb Blood Flow Metab 35:37–47. https://doi.org/10.1038/jcbfm.2014.162
Wultsch T, Grimberg G, Schmitt A, Painsipp E, Wetzstein H, Breitenkamp AFS, Gründemann D, Schömig E, Lesch K-P, Gerlach M, Reif A (2009) Decreased anxiety in mice lacking the organic cation transporter 3. J Neural Transm (Vienna) 116:689–697. https://doi.org/10.1007/s00702-009-0205-1
Yee SW, Brackman DJ, Ennis EA, Sugiyama Y, Kamdem LK, Blanchard R, Galetin A, Zhang L, Giacomini KM (2018) Influence of transporter polymorphisms on drug disposition and response: a perspective from the international transporter consortium. Clin Pharmacol Ther 104:803–817. https://doi.org/10.1002/cpt.1098
Zhang L, Dong Y, Doyon WM, Dani JA (2012) Withdrawal from chronic nicotine exposure alters dopamine signaling dynamics in the nucleus accumbens. Biol Psychiatry 71:184–191. https://doi.org/10.1016/j.biopsych.2011.07.024
Acknowledgments
The authors’ work on the genetic and epigenetic regulation of OCT transporters is supported by the Robert Bosch Stiftung (Stuttgart, Germany) and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy – EXC 2180 – 390900677.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Kölz, C., Schaeffeler, E., Schwab, M., Nies, A.T. (2021). Genetic and Epigenetic Regulation of Organic Cation Transporters. In: Daws, L.C. (eds) Organic Cation Transporters in the Central Nervous System. Handbook of Experimental Pharmacology, vol 266. Springer, Cham. https://doi.org/10.1007/164_2021_450
Download citation
DOI: https://doi.org/10.1007/164_2021_450
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-82983-4
Online ISBN: 978-3-030-82984-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)